LENZ Therapeutics Q3 2025 net loss $16.7M; VIZZ launch with 5K+ prescriptions in October

LENZ Therapeutics, Inc.

2025-Q3 EPS reported -$1.65 vs consensus -$0.72 ▼ miss (-129.0%)

Net loss $16.7M ($0.59/share) vs $10.2M in Q3 2024; R&D spend down to $3.8M.
SG&A expenses surged to $27.6M ($6.5M Q3 2024) from commercial launch infrastructure.
Pro forma cash $324M after $123.5M ATM raise in Oct 2025, extending runway to post-launch cash flow positive.
VIZZ (aceclidine) launched Oct 2025 with >2,500 unique prescribers and >5,000 prescriptions filled through Oct.
Partnered with Sarah Jessica Parker for DTC campaign starting Q1 2026; Canada deal with Théa worth >$70M in milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.